PD-1/PD-L1 inhibitors combined with Centipeda minima in lung cancer
Lung Cancer
Enrolment: 8 · Results not recorded
Loading the evidence…
Nutraceutical · Sesquiterpene lactone NF-kappaB (p65 Cys38) inhibitor; no ChEMBL record returned under 'helenalin'. FLAGGED: to_trial=true rests on a crude Centipeda minima herbal preparation, i.e. source-plant extract-level evidence rather than purified helenalin, and the trial is an oncology combination study unrelated to the trauma indication.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Lung Cancer
Enrolment: 8 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Lipopolysaccharide (50 microgram/kg) plus D-galactosamine (800 mg/kg) induced acute liver injury
Helenalin reduced histopathological liver damage, serum aminotransferase and bilirubin levels, hepatocyte apoptosis, oxidative stress and inflammatory cytokine production in lipopolysaccharide/D-galactosamine-induced acute liver injury.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.